Get In Touch

Rise in Sales of Bioreactors Due to High COVID-19 Vaccine Demand

Since hormones, fusion proteins, and vaccines form an important part of biologics, bioreactor sales are witnessing an upsurge during the COVID-19 outbreak. Such trends are contributing to the growth of the Asia Pacific biologics contract manufacturing market. Bioreactor sales have registered a notable increase during 2020 with many companies expanding their facilities in order to fulfil the demand for COVID-19 vaccine production.

Nationwide vaccination programs are creating revenue opportunities for stakeholders in the Asia Pacific biologics contract manufacturing market. The increasing government focus on encouraging the growth of local biotech companies by offering direct investments, tax incentives, and other resources is growing prominent in countries of Asia Pacific. Since vaccination is an underutilized public health intervention, stakeholders are working closely with governments to deploy initiatives for immunization of populations.

Request a sample to get extensive insights into the Biologics Contract Manufacturing Market

Can Process Intensification Tide Over Hurdles in Biologics Contract Manufacturing?

The patient-specific therapy is gaining importance for biopharmaceutical research. Biologics manufacturing challenges can emerge in multiple areas, but leading bio-manufacturers are addressing these difficulties with the help of process intensification (PI). Process intensification refers to a list of comprehensive initiatives that can maximize the efficiency of a bioprocess and make a biologic product more successful.

The perennial problem of productivity is affecting the growth of the Asia Pacific biologics contract manufacturing market. Thus, process intensification holds promising potentials to help introduce new products in a shorter period of time. With greater production capacity, biopharma organizations can scale their processes to meet patient demands.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Optimized Digital Manufacturing Helps Accelerate Product Innovations

The Asia Pacific biologics contract manufacturing market is expected to register a CAGR of 14.5% during the forecast period. In order to overcome challenges in biologics contract manufacturing, optimized digital manufacturing is gaining prominence as an essential remedy to boost productivity levels and adhere to high compliance standards. This strategy is helping biopharma organizations to become more technologically progressive and adaptive than other manufacturers.

Optimized digital manufacturing is helping companies in the Asia Pacific biologics contract manufacturing market to accelerate product innovations and ramp-up projects as per market demand trends. The automation of manufacturing processes is another key driver of the market.

Steep Cost of Biologics Acting as Barrier to Patient Access

The Asia Pacific biologics contract manufacturing market is projected to reach the valuation of US$ 9.8 Bn by 2031. The high prevalence of cancer is catalyzing the demand for biologics. However, the steep cost of these drugs is acting as a barrier to patient access. Nevertheless, patents in several oncology biologics are predicted to expire during the upcoming years, which is creating an opportunity for companies to introduce cost-efficient biosimilars.

Pharmaceutical manufacturers in the Asia Pacific biologics contract manufacturing market are shifting their focus from generics and joining the fray motivated by advantageous global and local regulations. For instance, Celltrion - a biopharmaceutical company headquartered in Incheon, South Korea, is acquiring recognition for successfully gaining regulatory approval in Europe companies with infliximab, a monoclonal antibody.

Strong Intent of Asian Companies to Bring Biosilimars into Western Markets

Even though patients may find the price of biologics to be high, Asia-based companies are at an advantageous position, since a lower cost base relative to countries in Europe and the U.S. is grabbing attention of stakeholders. Companies in the Asia Pacific biologics contract manufacturing market are capitalizing on low capital expenditure for manufacturing facilities, low biosimilar development costs, and cost efficient labor to advance in the healthcare landscape.

In China, a regulatory change permitting pharmaceutical companies to outsource manufacturing to CMOs (Contract Manufacturing Organizations) has led to new opportunities for biotechs to concentrate on innovative drug development. There is a strong intent of companies located in Asia to bring biosilimars into western markets.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Biologics Contract Manufacturing Market

Analysts’ Viewpoint

Companies in the Asia Pacific biologics contract manufacturing market are upgrading their infrastructure to accelerate the process development of COVID-19 vaccines. With the help of process intensification, stakeholders are deploying services that boost production whilst reducing the carbon footprint. Although biosimilars offer a similar clinical outcome as their reference counterparts at a reduced price, it is still important for manufacturers to seek recognition in the U.S., which limits its uptake. Nevertheless, biopharma organizations in Asia Pacific should stay flexible and respond to changing demands of patients. Research breakthroughs and new molecule discoveries are contributing to market expansion. The process intensification can help bio-manufacturing efforts become more responsive as technologies evolve rapidly.

Asia Pacific Biologics Contract Manufacturing Market: Overview

  • According to Transparency Market Research’s latest research report on the biologics contract manufacturing market in Asia Pacific for the historical year 2020 and the forecast period from 2021 to 2031, increase in sales of biopharmaceuticals and number of molecules in the pipeline being developed by small and virtual biotech companies are projected to drive the demand for biologics contract manufacturing during the forecast period
  • The biologics contract manufacturing market in Asia Pacific is anticipated to reach US$ 9.8 Bn by 2031, expanding at a CAGR of 14.5% from 2021 to 2031. Rest of Asia Pacific is projected to be a highly attractive market during the forecast period, with attractiveness index of 1.1. The region accounted for 41.7% share of the market in 2020. The sub-region's dominance can be attributed to the presence of China.
  • Based on type, the monoclonal antibodies segment held major market share in 2020. The segment’s dominance can be attributed to increase in adoption of monoclonal antibodies for large unmet medical needs in the fields of oncology and autoimmune disorders.

Increase in Demand for Biopharmaceutical Contract Manufacturing Services: Key Driver

  • Countries in Asia are emerging as desirable outsourcing destinations for the biopharmaceutical industry. Low manufacturing and operating costs in China and India are the key drivers of the contract manufacturing market in Asia Pacific. Due to low labor wages, pharmaceutical companies in China can reduce their manufacturing costs by 30% to 35%. Moreover, favorable tax incentives and an undervalued currency are likely to drive the market in the region during the forecast period. Growth of the biopharmaceutical industry in China and India is projected to propel the biopharmaceutical contract manufacturing market in Asia Pacific.

Growth of Vaccines Segment: Major Driver

  • The threat of new diseases and pandemics such as COVID-19 has spurred the development of biologic vaccines. Increase in incidence of infectious diseases is projected to drive the vaccines segment during the forecast period.

Asia Pacific Biologics Contract Manufacturing Market: Competition Landscape

  • Detailed profiles of biologics contract manufacturers have been provided in the biologics contract manufacturing market report to evaluate their financials, key product offerings, recent developments, and strategies
  • Key providers of biologics contract manufacturing focus on designing advanced and cost-effective solutions to leading biopharmaceuticals organizations
  • Major companies operating in Asia Pacific biologics contract manufacturing markets are
    • Lonza Group
    • Samsung Biologics Co., Ltd.
    • Patheon by Thermo Fisher Scientific, Inc.
    • Cambrex Corporation
    • Siegfried Holding AG
    • Others

Asia Pacific Biologics Contract Manufacturing Market Snapshot

Attribute

Detail

Market Size Value in 2020 (Base Year)

US$ 2.4 Bn

Market Forecast Value in 2031

US$ 9.8 Bn

Growth Rate (CAGR)

14.5%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, supply chain analysis, and parent industry overview.

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Monoclonal
    • Antibodies
    • Recombinant
    • Proteins
    • Vaccines
    • Molecular Therapy
    • Others

Regions Covered

  • Asia Pacific

Countries Covered

  • Japan
  • South Korea
  • Taiwan
  • Singapore
  • Thailand
  • India
  • Rest of Asia Pacific

Companies Covered

  • Lonza Group
  • Samsung Biologics Co., Ltd.
  • Patheon by Thermo Fisher Scientific, Inc.
  • Cambrex Corporation
  • Siegfried Holding AG
  • Fujifilm Holding Corporation
  • AbbVie, Inc.
  • Boehringer Ingelheim
  • Recipharm Pharmaceuticals
  • WuXi Biologics
  • Catalent, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Asia Pacific Biologics Contract Manufacturing Market – Scope of Report

The latest study collated and published by Transparency Market Research (TMR) analyzes the historical and present scenario of the biologics contract manufacturing market in Asia Pacific to gauge its growth potential. The study presents detailed information about important growth factors, restraints, and key trends that are creating the landscape for growth of the biologics contract manufacturing market in Asia Pacific in order to identify opportunities for stakeholders. The report also provides insightful information about the growth of the biologics contract manufacturing market in Asia Pacific during the forecast period from 2021 to 2031.

The report offers intricate dynamics about different aspects of the biologics contract manufacturing market in Asia Pacific, which aids companies operating in the market in making strategic decisions. TMR’s study also elaborates on the significant changes that are anticipated to boost the growth of the biologics contract manufacturing market in Asia Pacific during the forecast period. It also includes key indicator assessment that highlights growth prospects of the biologics contract manufacturing market in Asia Pacific and provides statistics related to the market in terms of value (US$ Mn).

This study covers detailed segmentation of the biologics contract manufacturing market in Asia Pacific, along with key information and competition outlook. The report provides company profiles of players that dominate the biologics contract manufacturing market in Asia Pacific, wherein various developments, expansions, and winning strategies adopted by these players have been presented in detail.

Key Questions Answered in TMR’s Report on Asia Pacific Biologics Contract Manufacturing Market

The report provides detailed information about the biologics contract manufacturing market in Asia Pacific based on comprehensive research on various factors that play a key role in accelerating the growth of the market. Information mentioned in the report answers path-breaking questions for companies that currently operate in the biologics contract manufacturing market in Asia Pacific and are looking for innovative methods to create a unique benchmark in the market in order to help them design successful strategies and make target-driven decisions.

  • Which segment of the biologics contract manufacturing market in Asia Pacific would emerge as a major revenue generator during the forecast period?
  • How are key market players successfully earning revenue in the biologics contract manufacturing market in Asia Pacific?
  • What would be the Y-o-Y growth trend of the biologics contract manufacturing market in Asia Pacific between 2021 and 2031?
  • What are the winning imperatives of leading players operating in the biologics contract manufacturing market in Asia Pacific?

Research Methodology – Asia Pacific Biologics Contract Manufacturing Market

The research methodology adopted by analysts for compiling the report on the biologics contract manufacturing market in Asia Pacific is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information obtained and endorsed by market-admissible sources, analysts have offered riveting observations and authentic forecasts of the biologics contract manufacturing market in Asia Pacific.

Primary research involved interviews with market stakeholders, investors, brand managers, vice presidents, and sales & marketing managers. Based on data obtained through interviews of genuine sources, analysts have emphasized the changing scenario of the biologics contract manufacturing market in Asia Pacific.

Secondary research involved study of annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the biologics contract manufacturing market in Asia Pacific.

Asia Pacific Biologics Contract Manufacturing Market – Segmentation

TMR’s research study assesses the biologics contract manufacturing market in Asia Pacific based on type and country. The report presents extensive market dynamics and progressive trends associated with different segments and how they influence growth prospects of the biologics contract manufacturing market in Asia Pacific.

Type
  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Molecular Therapy
  • Others
Country
  • Japan
  • South Korea
  • Taiwan
  • Singapore
  • Thailand
  • India
  • Rest of Asia Pacific

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Asia Pacific Biologics Contract Manufacturing Market